The latest recommendations from the American National Comprehensive Cancer Network (NCCN) for the diagnosis and treatment of myelodysplastic syndrome (MDS) include several updates incorporated into the graphical algorithms. Most patients with MDS have low-risk (LR) disease. We provide a summary of the current guidelines NCCN for the therapy of this group of patients, which differ depending on the presence of symptomatic anemia or clinically relevant thrombocytopenia or neutropenia.
Don‘t have an account? Create new account
Enter the email address that you registered with. We will send you instructions on how to set a new password.
